News

Regeneron Pharma and Bayer said that the primary endpoint was statistical non-inferiority in the proportion of patients who maintained (or improved) vision over 52 weeks compared to Ranibizumab.

Data for the analysis were from two Phases of the clinical trial, a double-blind, randomised, relapse-prevention maintenance phase that compared Invega Sustenna to placebo and a one-year open-label

Accolate, an oral prescription medicine used to treat asthma, works by blocking substances in the body called leukotrienes, which may contribute to the asthma symptoms. On 15 November

An IND application clinical hold is an order that the FDA issues to a clinical trial sponsor to postpone approval to conduct a proposed trial pending resolution of

CyDex claimed that the new product is a premixed intravenous (IV) bag formulation of Prism Pharmaceuticals’ Nexterone injection, which was the first CyDex licensed proprietary product to achieve

As per the terms of the agreement, Boehringer Ingelheim will nominate up to seven targets, which may span multiple therapeutic areas, against which the parties will collaborate to

As per the terms of the agreement, Convergence Pharma will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise, recently formed out of GlaxoSmithKline

CTI said that in the current study, patients received PPX with TMZ and RT for six weeks and the main toxicity was grade 4 thrombocytopenia and neutropenia in

The minority shares are currently owned by University of Colorado (CU) chemists Lajos Gera and Robert Hodges (the minority shareholders) who have granted the sole and exclusive option